Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239131 | 0.88 | HRH3 (0.62) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL30717258 | 0.86 | PARP10 (0.58) | ALDH1A1SENP8SENP6HRH3KMT2A | |
| SCHEMBL4236787 | 0.86 | HRH3 (0.54) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL4228646 | 0.85 | HRH3 (0.70) | HRH3SRD5A1 | |
| SCHEMBL23513579 | 0.81 | HRH3 (0.46) | ALDH1A1HRH3KMT2A | |
| SCHEMBL23497369 | 0.81 | ACACB (0.51) | ALDH1A1LMNATDP1HRH3EPHX2 | |
| SCHEMBL17542061 | 0.81 | SRD5A1 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL12030786 | 0.80 | SLC6A2 (0.51) | HRH3 | |
| SCHEMBL12030766 | 0.78 | PDE9A (0.47) | HRH3 | |
| SCHEMBL10057698 | 0.77 | HRH3 (0.45) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | disclosed |
| CN-115279747-B | FYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| EP-4073057-B1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2023-11-29 | — | — | EP | disclosed |
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-03-02 | — | — | US | disclosed |
| CN-115279747-A | Novel fYN and VEGFR2 kinase inhibitors | 罗达制药生物技术有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4073057-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2022-10-19 | — | — | EP | disclosed |
| WO-2021116005-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116005-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115560-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | ALDH1A1 4279/4885LMNA 4494/4885CASP3 2786/4885 |
| US-20230061118-A1 | NEW FYN AND VEGFR2 KINASE INHIBITORS | FYN, SRC, PTK2B | ALDH1A1 3582/4885LMNA 4354/4885CASP3 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.